

Remarks

The above amendments have been made to place the instant Continuation in proper form for examination.

The two lines immediately following the title have been canceled and replaced with a new paragraph updating the status of this application as a continuation of US Patent Application No. 09/495,061, filed January 31, 2000, which claims the benefit of Provisional Application No. 60/119,406, filed February 10, 1999


Claims 1-48 from parent application 09/495,061 have been canceled and replaced by new claims 49-78.

Priority to all U. S. applications in the lineage of the instant application is hereby claimed. Priority of U. S. Application 09/495,061 filed January 31, 2000 is claimed under 35 USC §120. Priority of U. S. Provisional Application 60/119,406 is claimed under 35 USC §119(e).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: MARCH 11, 2004


James T. Jones
Attorney for Applicant(s)
Reg. No. 30,561

Pfizer Inc.
Patent Department, Box 8260-1611
Eastern Point Road
Groton, CT 06340
(860) 441-4903